|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||19.69 - 21.50|
|52 Week Range||11.85 - 42.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its initial public offering of 3,000,000 shares of common stock at a public offering price of $12.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 450,000 shares of common stock at the initial public offering price, less the underwriting discount. The shares are expected to begin trading on the Nasdaq Global Market on October 31, 2019, under the ticker symbol “RAPT.” The offering is expected to close on November 4, 2019, subject to the satisfaction of customary closing conditions.
The IPO calendar this week has a single biotech issue which has in its clinical pipeline, product candidates targeting oncology and inflammatory diseases. The IPO Terms San Francisco, California-based ...
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Dynatrace Holdings LLC (DT) will issue nearly 35.6 million shares between ...